Global Information
회사소개 | 문의 | 비교리스트

A형 간염 : 파이프라인 리뷰

Hepatitis A - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 219723
페이지 정보 영문 33 Pages
가격
US $ 2,000 ₩ 2,402,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,804,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,206,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


A형 간염 : 파이프라인 리뷰 Hepatitis A - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 33 Pages

A형 간염이란 A형 간염 바이러스에 대한 감염으로 발병하는 간의 염증(자극·부종)을 가리킵니다. 주요 증상으로 권태감 및 구역·구토, 간 염증, 식욕 부진, 암색뇨, 근육통, 황달 등을 들 수 있습니다. 주요 질병 소질에는 면역계의 약체화 및 위법 약물 사용(주사제·비주사제) 등이 포함됩니다. 주요 치료법으로 항구토제 및 진통제 등이 있습니다.

세계 각국에서의 A형 간염 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 파이프라인 제품의 최신 동향, 임상시험 각 단계의 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등을 조사하여 전해드립니다.

서론

  • 조사 범위

A형 간염 - 개요

A형 간염 - 치료제 개발

  • 파이프라인 개요
  • 기업별 파이프라인 동향
  • 대학·연구기관별 파이프라인 동향
  • 기업에서 개발중인 제품
  • 대학·연구기관에서 개발중인 제품

A형 간염 - 치료제 평가

  • 표적별
  • 분자 종류별

A형 간염 치료제 개발에 참여하고 있는 기업

  • Beijing Minhai Biotechnology Co Ltd
  • Indian Immunologicals Ltd
  • Sinovac Biotech Ltd
  • Zydus Cadila Healthcare Ltd

약제 개요

A형 간염 - 휴지중인 프로젝트

부록

KSA 17.06.13

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Hepatitis A, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Hepatitis A - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
  • Hepatitis A - Pipeline by Biological E Ltd, H1 2020
  • Hepatitis A - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2020
  • Hepatitis A - Pipeline by China National Pharmaceutical Group Corp, H1 2020
  • Hepatitis A - Pipeline by Etna Biotech Srl, H1 2020
  • Hepatitis A - Pipeline by Indian Immunologicals Ltd, H1 2020
  • Hepatitis A - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, H1 2020
  • Hepatitis A - Pipeline by Novo Medi Sciences Pvt Ltd, H1 2020
  • Hepatitis A - Pipeline by Sinovac Biotech Ltd, H1 2020
  • Hepatitis A - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Hepatitis A, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis A - Pipeline Review, H1 2020, provides an overview of the Hepatitis A (Infectious Disease) pipeline landscape.

Hepatitis A is inflammation of the liver caused by hepatitis A virus. Symptoms include fatigue, nausea and vomiting, inflammation of the liver, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes (jaundice). Risk factors include weakened immune system and use injected or non-injected illicit drugs. Treatment includes antiemetics and pain relievers.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis A - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hepatitis A (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis A (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed and Unknown stages are 4, 3, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hepatitis A (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis A (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis A (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis A (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis A (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis A (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis A (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis A (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hepatitis A - Overview
    • Hepatitis A - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Hepatitis A - Therapeutics Assessment
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hepatitis A - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co Ltd
    • Biological E Ltd
    • Boryung Pharmaceutical Co Ltd
    • China National Pharmaceutical Group Corp
    • Etna Biotech Srl
    • Indian Immunologicals Ltd
    • Liaoning Cheng Da Biotechnology Co Ltd
    • Novo Medi Sciences Pvt Ltd
    • Sinovac Biotech Ltd
  • Hepatitis A - Drug Profiles
    • BR-8003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A + hepatitis B vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hepatitis A - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q